Page 2426 - Williams Hematology ( PDFDrive )

2397
2396 Index Index 2397

AH50, 1232 porphyria cutanea tarda and, 906 Alloimmune hemolytic anemia, 836
aHUS (atypical hemolytic uremic syndrome), thrombocytopenia in, 1998 Alloimmune hemolytic disease of the fetus
2259–2261, 2259t ALDOA, 695 and newborn (HDFN), 847–859
AI. See Anemia of inflammation (AI) Aldolase antenatal monitoring, 853f
AICAR, 585, 590 activity, 692t amniotic fluid spectrophotometry in,
AICC (anti-inhibitor coagulant complex), deficiency, 700t, 704 854
2185 in glucose metabolism, 695 fetal blood sampling, 854
AID (activation-induced deaminase), 1169, Aldosteronism, 560 maternal immunohematologic testing,
1213, 1214t, 1215, 1710 Alefacept, for acquired aplastic anemia, 527 852–853
AIDS (acquired immunodeficiency Alemtuzumab, 345 paternal zygosity/fetal blood type, 852
syndrome). See also Human adverse effects, 343t, 1535, 1695 ultrasonography, 854, 855f
immunodeficiency virus (HIV) for autoimmune hemolytic anemia, 839 clinical features, 848–849
infection for B-cell prolymphocytic leukemia, 1542 definition and history, 847, 2329
acute myelogenous leukemia and, 1375 for chronic lymphocytic leukemia, 1535 differential diagnosis, 849
cobalamin deficiency and, 601–602 dose, 343t epidemiology, 847–848, 848t
diagnosis, 1240–1242, 1241t for mycosis fungoides, 1687 obstetric history and, 849
malignancies associated with. See Human for myelodysplastic syndromes, 1359 outcome, 858
immunodeficiency virus for peripheral T-cell lymphoma, 1695 pathophysiology
(HIV)–associated malignancies for pure red cell aplasia, 544 ABO hemolytic disease, 851, 852t, 2330,
natural killer cells and, 1192 for reduced intensity conditioning, 1115 2348
opportunistic infections in, 1240–1241, for T-cell large granular lymphocytic Kell hemolytic disease, 851
1241t leukemia, 1567 minor RBC antigens, 851
AIDS-defining conditions, 1240–1241, 1241t, ALG (antilymphocyte serum), 522 RhD hemolytic disease, 849–850, 851f,
1243, 1243t, 1244f Alglucerase, for Gaucher disease, 1127 852t, 2348
AIP. See Acute intermittent porphyria (AIP) ALK, 188, 1576 prevention, 858–859, 859f, 2339
AIRE, 1181, 1219, 1224 ALK-1, 1688 therapy, 854–858
Airway hyperreactivity ALK-positive large B-cell lymphoma, 1496t, delivery, 855
eosinophilia and, 954 1598–1599 erythropoietin, 859
sickle cell disease and, 769 ALK-positive/negative anaplastic large cell exchange transfusion, 856–857
AITL (angioimmunoblastic T-cell lymphoma. See Anaplastic large cell immediate postnatal, 856
lymphoma), 1498t, 1598, 1694, lymphoma (ALCL) intrauterine transfusion, 854–855
1694t, 1697–1698 Alkylating drugs, 329–331. See also specific IVIG, 858–859
Ajoene, 2079 drugs neonatal monitoring, 855–856, 856f
AK (adenylate kinase), 692t, 699, 700t, 705 adverse effects, 330–331 phototherapy, 857
AK1, 699 for chronic lymphocytic leukemia, 1534 Alloimmune neonatal neutropenia, 995, 2358
A knobs, fibrin, 2152, 2153f, 2158 high-dose, 331, 331t Allopurinol, 322
AKT, 209, 1666 mechanism of action, 329, 330f for acute lymphoblastic leukemia, 1505,
Akt (protein kinase B), 208f, 209, 251, 1882 pharmacology, 329–330 1514
AKT inhibitors, 1403 resistance to, 319t for hyperuricemia, 1394, 1450, 1514
ALA (δ-aminolevulinic acid), 889, 891f, 893f secondary acute myelogenous leukemia Allotypes, immunoglobulin, 1170–1171
ALAD (δ-aminolevulinate dehydratase), 894 and, 1407 All-trans-retinoic acid. See ATRA (all-trans-
ALA (δ-aminolevulinic acid) dehydrase, 701t ALL. See Acute lymphoblastic (lymphocytic) retinoic acid)
AL amyloidosis. See Immunoglobulin light- leukemia (ALL) Alopecia, 632, 1223
chain (AL) amyloidosis Allele-specific oligonucleotide polymerase ALOX5AP, 2288
ALAS (δ-aminolevulinate synthase), chain reaction (ASO-PCR), 1716 ALOX12, 2060
892–894, 917–918 Allelic exclusion, 1168 α2a adrenergic receptors, 1876
ALAS1, 892–894, 896, 901 Allergic disorders αβ heterodimers, 1175, 1176f
ALAS2, 892–894, 896, 918 basophils and mast cells in, 969 α β interface, mutations in, 781
1 1
ALAS2, 894, 916, 920 eosinophilia in, 955t αβ T-cell receptor, 1177
ALCL. See Anaplastic large cell lymphoma Allergic irritability, 303 α-chain (AM) allotypes, 1170
(ALCL) Allergic transfusion reaction, 2375 α chemokines, 288, 288t
Alcohol abuse Alloantibodies, 2343 αδ-storage pool deficiency, 2055
acquired stomatocytosis in, 684 Allogeneic hematopoietic stem cell α-enolase, 696
hematologic effects, 654–655 transplantation. See Hematopoietic α-globin chains
lymphocytopenia in, 1206 cell transplantation (HCT), β-thalassemias and, 742
neutrophil motility and, 1026 allogeneic hemoglobin, 728, 760–761

Kaushansky_index_p2393-2506.indd 2397 9/21/15 3:21 PM